SI
SI
discoversearch

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor.  We ask that you disable ad blocking while on Silicon Investor in the best interests of our community.  If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.
Biotech / Medical : AXCAN Pharma(AXCA)..A GUT FEELING!

 Public ReplyPrvt ReplyMark as Last ReadFilePrevious 10Next 10PreviousNext  
To: Zeev Hed who wrote (14)8/19/2000 9:21:11 PM
From: Biomaven  Read Replies (2) of 46
 
Zeev,

The drug only works at all on some types of gallstones (non-calcified cholesterol-based stones); you need to demonstrate proper gall bladder function first (which entails a cholecystography); you then need to take an expensive drug for many months that apparently only works about 30-40% of the time. If you do succeed in dissolving the stones, they frequently recur. Further, some doctors are concerned that attempting to dissolve the stones makes it more likely that a partially-dissolved stone or fragment will end up lodged in your bile duct or (worse) common duct and cause a ductal obstruction, which can be serious.

Gall-bladder surgery is nowadays typically same-day surgery with a very quick recovery. One unforeseen disadvantage of this will soon be apparent - Pat Buchanan will likely be back on the campaign trail in no time at all. <g>

Here's an abstract:

Q J Med 1990 Jul;76(279):711-29 Related Articles, Books, LinkOut

Final outcome of ursodeoxycholic acid treatment in 126 patients with radiolucent gallstones.

Gleeson D, Ruppin DC, Saunders A, Murphy GM, Dowling RH

Gastroenterology Unit, UMDS of Guy's, Hospital, London, UK.

One hundred and twenty-six patients with radiolucent gallstones in 'functioning' gallbladders were treated with 8-10 mg ursodeoxycholic acid (UDCA) kg/day and followed to a treatment conclusion. Complete or partial gallstone dissolution was achieved in 74 (59 per cent). However, only 22 achieved complete gallstone dissolution, as judged by two normal oral cholecystograms; ultrasonograms were performed in 16 of these patients, and all were normal. UDCA was stopped in 76 patients: because of cystic duct obstruction (n = 12), severe biliary pain (n = 13), non-response (n = 25) or partial stone dissolution with arrested progress (n = 26). Life-table analysis showed that complete gallstone dissolution rates at four years were 25-30 per cent (two normal oral cholecystograms) and 17-19 per cent (two normal oral cholecystograms plus one ultrasonogram). All patients with complete gallstone dissolution had shown partial stone dissolution at 6-12 months; of those with partial stone dissolution at six months, only 25 per cent went on to complete gallstone dissolution, and then always within two years. Efficacy correlated inversely with stone size but not with age, sex, obesity or on-treatment saturation indices. Acquired surface gallstone calcification developed in 13 patients (life-table analysis 22 +/- 7 per cent at four years); none of these patients achieved complete gallstone dissolution and only five achieved partial stone dissolution. Thus, despite relatively high partial gallstone dissolution rates, the ultimate efficacy of UDCA in achieving complete gallstone dissolution is low.


The Axcan drug is apparently used in primary biliary cirrhosis, though.

Peter
Report TOU ViolationShare This Post
 Public ReplyPrvt ReplyMark as Last ReadFilePrevious 10Next 10PreviousNext